81 related articles for article (PubMed ID: 35266034)
21. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study.
López-Medina C; Calvo-Gutiérrez J; Ábalos-Aguilera MC; Cepas F; Plasencia-Rodríguez C; Martínez-Feito A; Balsa A; Faré-García R; Juan-Mas A; Ruiz-Esquide V; Sainz L; Díaz-Torné C; Godoy-Navarrete FJ; Añón-Oñate I; Mena-Vázquez N; Manrique-Arija S; Moreno-García MS; Ortega-Castro R; Escudero-Contreras A
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38395455
[TBL] [Abstract][Full Text] [Related]
22. Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis.
Triaille C; Quartier P; De Somer L; Durez P; Lauwerys BR; Verschueren P; Taylor PC; Wouters C
Rheumatology (Oxford); 2024 Mar; 63(3):594-607. PubMed ID: 37725352
[TBL] [Abstract][Full Text] [Related]
23. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.
Evangelatos G; Bamias G; Kitas GD; Kollias G; Sfikakis PP
Rheumatol Int; 2022 Sep; 42(9):1493-1511. PubMed ID: 35503130
[TBL] [Abstract][Full Text] [Related]
24. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
25. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
Eng GP
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
[TBL] [Abstract][Full Text] [Related]
26. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
Nakayama Y; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A; Hashimoto M
Rheumatol Int; 2022 Jul; 42(7):1227-1234. PubMed ID: 35266034
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
[TBL] [Abstract][Full Text] [Related]
28. Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients.
Yang Y; Wu B; Tian P; Huang L
Int J Rheum Dis; 2023 Aug; 26(8):1521-1528. PubMed ID: 37382403
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
[TBL] [Abstract][Full Text] [Related]
30. Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.
Berkhout LC; I'Ami MJ; Kruithof S; Vogelzang EH; Hooijberg F; Hart MHL; Bentlage AEH; Thomas D; Vermeire S; Vidarsson G; Ten Brinke A; Nurmohamed MT; Wolbink GJ; Rispens T
Br J Pharmacol; 2024 Apr; 181(8):1165-1181. PubMed ID: 37859583
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study.
Maeda Y; Hirano T; Ebina K; Hara R; Hashimoto M; Yamamoto W; Murakami K; Kotani T; Hata K; Son Y; Amuro H; Onishi A; Jinno S; Katayama M; Kumanogoh A
Rheumatol Int; 2021 Jul; 41(7):1233-1241. PubMed ID: 33903963
[TBL] [Abstract][Full Text] [Related]
33. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy.
Julià A; López-Lasanta M; Blanco F; Gómez A; Haro I; Mas AJ; Erra A; Vivar MLG; Monfort J; Sánchez-Fernández S; González I; Alperi M; Castellanos-Moreira R; Fernández-Nebro A; Díaz-Torné C; Palau N; Lastra R; Lladós J; Sanmartí R; Marsal S
BMC Musculoskelet Disord; 2021 Apr; 22(1):372. PubMed ID: 33882889
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
[TBL] [Abstract][Full Text] [Related]
35. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry.
Harrold LR; Shan Y; Rebello S; Kramer N; Connolly SE; Alemao E; Kelly S; Kremer JM; Rosenstein ED
Rheumatol Int; 2020 Aug; 40(8):1239-1248. PubMed ID: 32449040
[TBL] [Abstract][Full Text] [Related]
36. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
